Kairos Pharma
Filed with the SEC on · accession 0001493152-26-042569
KAPA filed a 8-K (current report) with the SEC on Sep 14, 2026. Kairos Pharma issued a new investor presentation and announced that CEO John Yu will present it at the H.C. The stock moved +4.7% by the first close after the filing.
Kairos Pharma issued a new investor presentation and announced that CEO John Yu will present it at the H.C. Wainwright 28th Annual Global Investment Conference, providing an update on the company's clinical program and activities.
Close before
$1.76
Sep 11, 2026
First close after
+4.66%
$1.84
5 trading days
-0.46%
$1.75
Since filing
-72.25%
$0.49
✦ Ask GOAX AI about this filing — what it means for KAPA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KAPA?
Click hereKAPA filed a 8-K (SEC filing). Kairos Pharma issued a new investor presentation and announced that CEO John Yu will present it at the H.C. Wainwright 28th Annual Global Investment Conference, providing an update on the company's clinical program and activities.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
KAPA closed at $1.76 before the filing and $1.84 on Sep 14, 2026 (+4.66%). Five trading days later: $1.75 (-0.46%).
Get alerts when KAPA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days